Abstract: The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.
Abstract: The present disclosure relates to administration of meloxicam intravenously, for treatment of pain, in patients who are at least 65 years old and have mild renal impairment, which can provide fast onset of pain relief suitable for management of acute pain as well as moderate to severe pain.
Type:
Grant
Filed:
March 8, 2019
Date of Patent:
January 5, 2021
Assignee:
BAUDAX BIO, INC.
Inventors:
Randall J. Mack, Stewart McCallum, Alexis Gomez, Alex Freyer
Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
August 25, 2019
Date of Patent:
July 14, 2020
Assignee:
BAUDAX BIO, INC.
Inventors:
Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
Abstract: The present invention provides intranasal formulations comprising dexmedetomidine, or a pharmaceutically acceptable salt thereof, and uses thereof.
Type:
Grant
Filed:
September 12, 2017
Date of Patent:
June 16, 2020
Assignee:
BAUDAX BIO, INC.
Inventors:
Geraldine A. Henwood, Randall J. Mack, John Joseph Koleng, Jr., Christopher T. Sharr, Charles A. Freyer
© 2024 Justia
